RESUMO
Radiation therapy (RT) plays a fundamental role in the treatment of malignant and benign brain tumors. Current state-of-the-art photon- and proton-based RT combines more conformal dose distribution of target volumes and accurate dose delivery while limiting the adverse radiation effects. PubMed was systematically searched from from 2000 to October 2023 to identify studies reporting outcomes related to treatment of central nervous system (CNS)/skull base tumors with PT in adults. Several studies have demonstrated that proton therapy (PT) provides a reduced dose to healthy brain parenchyma compared with photon-based (xRT) radiation techniques. However, whether dosimetric advantages translate into superior clinical outcomes for different adult brain tumors remains an open question. This review aims at critically reviewing the recent studies on PT in adult patients with brain tumors, including glioma, meningiomas, and chordomas, to explore its potential benefits compared with xRT.
RESUMO
BACKGROUND: Deterioration of neurocognitive function in adult patients with a primary brain tumor is the most concerning side effect of radiotherapy. This study aimed to develop and evaluate normal-tissue complication probability (NTCP) models using clinical and dose-volume measures for 6-month, 1-year, and 2-year Neurocognitive Decline (ND) postradiotherapy. METHODS: A total of 219 patients with a primary brain tumor treated with radical photon and/or proton radiotherapy (RT) between 2019 and 2022 were included. Controlled oral word association test, Hopkins verbal learning test-revised, and trail making test were used to objectively measure ND. A comprehensive set of potential clinical and dose-volume measures on several brain structures were considered for statistical modeling. Clinical, dose-volume and combined models were constructed and internally tested in terms of discrimination (area under the curve, AUC), calibration (mean absolute error, MAE), and net benefit. RESULTS: Fifty percent, 44.5%, and 42.7% of the patients developed ND at 6-month, 1-year, and 2-year time points, respectively. The following predictors were included in the combined model for 6-month ND: age at radiotherapyâ >â 56 years (ORâ =â 5.71), overweight (ORâ =â 0.49), obesity (ORâ =â 0.35), chemotherapy (ORâ =â 2.23), brain V20 Gyâ ≥â 20% (ORâ =â 3.53), brainstem volumeâ ≥â 26 cc (ORâ =â 0.39), and hypothalamus volumeâ ≥â 0.5 cc (ORâ =â 0.4). Decision curve analysis showed that the combined models had the highest net benefits at 6-month (AUCâ =â 0.79, MAEâ =â 0.021), 1-year (AUCâ =â 0.72, MAEâ =â 0.027), and 2-year (AUCâ =â 0.69, MAEâ =â 0.038) time points. CONCLUSIONS: The proposed NTCP models use easy-to-obtain predictors to identify patients at high risk of ND after brain RT. These models can potentially provide a base for RT-related decisions and post-therapy neurocognitive rehabilitation interventions.
Assuntos
Neoplasias Encefálicas , Irradiação Craniana , Humanos , Masculino , Feminino , Neoplasias Encefálicas/radioterapia , Pessoa de Meia-Idade , Irradiação Craniana/efeitos adversos , Adulto , Idoso , Lesões por Radiação/etiologia , Lesões por Radiação/diagnóstico , Seguimentos , Prognóstico , Transtornos Neurocognitivos/etiologia , Disfunção Cognitiva/etiologia , Fatores de RiscoRESUMO
This retrospective study examined bone flap displacement during radiotherapy in 25 post-operative brain tumour patients. Though never exceeding 2.5 mm, the sheer frequency of displacement highlights the need for future research on larger populations to validate its presence and assess the potential clinical impact on planning tumour volume margins.